Core Viewpoint - The company, 加科思-B (01167.HK), has entered into a licensing and collaboration agreement with AstraZeneca to develop and commercialize the pan-KRAS inhibitor JAB-23E73, which targets advanced solid tumors with KRAS gene mutations [1]. Group 1: Agreement Details - The agreement grants AstraZeneca exclusive rights to research, develop, register, manufacture, and commercialize JAB-23E73 globally, excluding China [1]. - 北京加科思 is entitled to receive an upfront payment of $100 million from AstraZeneca, with potential milestone payments totaling up to $1.915 billion based on the achievement of various development, regulatory, and commercial milestones [1]. - Upon successful commercialization of the licensed product, 北京加科思 will receive tiered royalties based on the net sales of the licensed product [1]. Group 2: Clinical Development - The Phase I clinical trial for JAB-23E73 is currently underway in China and the United States, targeting patients with advanced solid tumors carrying KRAS gene mutations [1]. - Future indications for JAB-23E73 are expected to expand to include pancreatic cancer (PDAC), non-small cell lung cancer (NSCLC), and colorectal cancer (CRC), all of which are associated with KRAS mutations [1].
加科思-B(01167.HK)附属与阿斯利康就JAB-23E73订立许可及合作协议